Why Penumbra (PEN) Shares Are Falling Today
Update: 2025-10-29
Description
Penumbra's STORM-PE trial results show their device, used with anticoagulation, outperforms drugs alone in treating serious lung blood clots, with significant improvement in two days and no increased side effects. Despite this positive news, Penumbra's stock dropped by over 5%, contrary to expectations. The stock has been volatile, with only nine other days of more than 5% movement in the past year. The reaction may seem confusing due to recent positive analyst reports and new products in the pipeline, like Thunderbolt and Ruby XL, expected to boost revenue and profits. However, Penumbra's stock is down 2.5% this year and trades below its highest price, leaving investors cautious despite the promising trial results.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
